Original articleGrowth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome
Section snippets
Study Design
The studies were carried out following a protocol approved by the Jewish Hospital Institutional Review Board, with signed informed consent. Growth, motor-social development, and intercurrent illnesses were prospectively studied at 3 and 6 months of age in 111 infants, 61 breast- and 50 formula-fed (Table I, Table II, Table III, Table IV), born to 92 metformin-treated women with PCOS, who had taken metformin (1.5-2.55 g/day) throughout pregnancy16, 18, 19 and continued metformin (1.5-2.55 g/day)
Results
We studied 61 breast-fed and 50 formula-fed infants born to 92 mothers with PCOS taking 1.5 to 2.55 g metformin per day throughout pregnancy and lactation (Table I). During lactation, the mean ± SD and median maternal metformin dose was 2.2 ± 0.5 and 2.55 g/day. Having taken metformin throughout pregnancy, compliance to the targeted metformin dose was excellent. Breast-feeding mothers did not differ from formula-feeding mothers by age at delivery or percentage with gestational diabetes, but
Discussion
Metformin is increasingly used during pregnancy in women with PCOS9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 29 because it promotes regular ovulation and conception; reduces first trimester miscarriage, gestational diabetes, and macrosomia; reduces severe pregnancy and post-partum complications9; and does not appear to be teratogenic.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 Because metformin ameliorates the endocrinopathy of PCOS,1, 2, 3, 4, 6, 30 it has been continued after delivery
References (35)
- et al.
Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
Metabolism
(1999) - et al.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
Metabolism
(1997) - et al.
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
Metabolism
(1994) - et al.
Metformin monotherapy in lean women with polycystic ovary syndrome
Reprod Biomed Online
(2005) - et al.
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortiona pilot study
Fertil Steril
(2001) - et al.
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome
Fertil Steril
(2002) - et al.
Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage
Fertil Steril
(2000) Polycystic ovary syndrome
N Engl J Med
(2005)- et al.
Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome
J Clin Endocrinol Metab
(2005) - et al.
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity
Obstet Gynecol Surv
(2005)
Polycystic ovary syndrome in adolescence. New insights in pathophysiology and treatment
Endocr Dev
Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome womenresults of a randomized study
Hum Reprod
The contentious nature of gestational diabetesdiet, insulin, glyburide and metformin
Expert Opin Pharmacother
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Hum Reprod
Metformin and gestational diabetes
Curr Diab Rep
Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin
Clin Appl Thromb Hemost
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Diabet Med
Cited by (0)
Supported by the Jewish Hospital Lipoprotein Research Fund and by the Medical Research Council of the Jewish Hospital.